Gyre Therapeutics (GYRE) Stock Price, News & Analysis

Company Overview

Gyre Therapeutics, Inc., a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases. In addition, it advances a product pipeline in China, including Pirfenidone, for dermatomyositis interstitial lung disease, systemic sclerosis-associated interstitial lung disease, and pneumoconiosis, as well as for diabetic kidney disease; and product candidates for acute-on-chronic liver failure, chronic obstructive pulmonary disease, and pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California.

Key Stats

• Today's Range: $10.99 to $11.67
• 50-Day Range: $6.41 to $12.28
• 52-Week Range: $6.11 to $19.00
• Volume: 140,695 shs
• Average Volume: 96,121 shs
• Market Capitalization: $1.06 billion
• P/E Ratio: 567.50
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Buy

Gyre Therapeutics Stock Analysis - MarketRank™

Gyre Therapeutics scored higher than 8% of companies evaluated by MarketBeat, and ranked 1833rd out of 1,850 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Gyre Therapeutics.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Gyre Therapeutics is 567.50, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 25.10.

Price to Earnings Ratio vs. Sector

The P/E ratio of Gyre Therapeutics is 567.50, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 27.02.

Price to Book Value per Share Ratio

Gyre Therapeutics has a P/B Ratio of 63.06. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

13.99% of the float of Gyre Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Gyre Therapeutics has a short interest ratio ("days to cover") of 15.9, which indicates bearish sentiment.

Change versus previous month

Short interest in Gyre Therapeutics has recently decreased by 5.20%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Gyre Therapeutics does not currently pay a dividend.

Dividend Growth

Gyre Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

13.99% of the float of Gyre Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Gyre Therapeutics has a short interest ratio ("days to cover") of 15.9, which indicates bearish sentiment.

Change versus previous month

Short interest in Gyre Therapeutics has recently decreased by 5.20%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.4 / 5
• News Sentiment: 0.39

News Sentiment

Gyre Therapeutics has a news sentiment score of 0.39. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Gyre Therapeutics this week, compared to 2 articles on an average week.

Search Interest

2 people have searched for GYRE on MarketBeat in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Gyre Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $133,320.00 in company stock.

Percentage Held by Insiders

19.52% of the stock of Gyre Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 23.99% of the stock of Gyre Therapeutics is held by institutions.

GYRE Stock Analysis - Frequently Asked Questions

How have GYRE shares performed this year?

Gyre Therapeutics' stock was trading at $12.10 at the beginning of the year. Since then, GYRE stock has decreased by 6.2% and is now trading at $11.35.
View the best growth stocks for 2025 here.

How were Gyre Therapeutics' earnings last quarter?

Gyre Therapeutics, Inc. (NASDAQ:GYRE) posted its quarterly earnings data on Friday, May, 9th. The company reported $0.03 EPS for the quarter, hitting analysts' consensus estimates of $0.03. The firm earned $22.06 million during the quarter, compared to analysts' expectations of $28.40 million. Gyre Therapeutics had a negative net margin of 84.57% and a negative trailing twelve-month return on equity of 118.43%.

Who are Gyre Therapeutics' major shareholders?

Gyre Therapeutics' top institutional shareholders include SBI Securities Co. Ltd. (0.13%), Charles Schwab Investment Management Inc. (0.12%), American Century Companies Inc. (0.03%) and Bank of New York Mellon Corp (0.02%). Insiders that own company stock include Songjiang Ma and Nassim Usman.
View institutional ownership trends.

How do I buy shares of Gyre Therapeutics?

Shares of GYRE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Gyre Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Gyre Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Netflix (NFLX), Broadcom (AVGO), Palo Alto Networks (PANW) and Invesco QQQ (QQQ).

Company Calendar

• Last Earnings: 5/09/2025
• Today: 5/18/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:GYRE
• Previous Symbol: NASDAQ:GYRE
• CIK: 1124105
• Web: www.catalystbiosciences.com
• Phone: (619) 949-3681
• Fax: 336-480-2107
• Employees: 40
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): $0.02
• Trailing P/E Ratio: 567.50
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-92,930,000.00
• Net Margins: -84.57%
• Pretax Margin: -74.10%
• Return on Equity: -118.43%
• Return on Assets: -71.97%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.72
• Quick Ratio: 3.29

Sales & Book Value

• Annual Sales: $100.64 million
• Price / Sales: 10.57
• Cash Flow: $0.22 per share
• Price / Cash Flow: 50.49
• Book Value: $0.18 per share
• Price / Book: 63.06

Miscellaneous

• Outstanding Shares: 93,758,000
• Free Float: 75,266,000
• Market Cap: $1.06 billion
• Optionable: No Data
• Beta: 1.90